Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study
- 260 Downloads
Purpose: To evaluate the efficacy and safety of amrubicin, (+)-(7S, 9S)-9-acetyl-9-amino-7-[(2-deoxy-β-D-erythro-pentopyranosyl )oxy ]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione hydrochloride, in previously untreated patients with extensive-disease small cell lung cancer (SCLC).
Patients and methods: A total of 35 previously untreated patients with extensive-disease SCLC were entered into the study. Amrubicin was given by daily intravenous infusion at 45 mg/m2/day for 3 consecutive days, every 3 weeks. Unless there was tumor regression of 25% or greater after the first cycle, or 50% or greater after the second cycle, treatment was switched to salvage chemotherapy in combination with etoposide (100 mg/m2, days 1, 2, and 3) and cisplatin (80 mg/m2, day 1).
Results: Of the 35 patients entered, 33 were eligible and assessable for efficacy and toxicity. Of the 33 patients, 3 (9.1%) had a complete response (95% confidence interval [CI], 1.9–24.3%) and 22 had a partial response, for an overall response rate of 75.8% (95% CI, 57.7–88.9%). Median survival time was 11.7 months (95% CI, 9.9–15.3 months), and 1-year and 2-year survival rates were 48.5% and 20.2%, respectively. The most common toxicity was hematologic. Non-hematologic toxicity of grade 3 or 4 was only seen in 3 patients with anorexia (9.1%) and 1 patient with alopecia (3.0%). Salvage chemotherapy was administered to only 6 patients.
Conclusion: Amrubicin was active for extensive-disease SCLC with acceptable toxicity. Further studies in combination with other agents for SCLC are warranted.
KeywordsAmrubicin Small cell lung cancer Anthracycline Previously untreated patients Phase II study
- 1.Murren J, Glatstein E, Pass H (2001) Small cell lung cancer. In: DeVita VTJ, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott Williams and Wilkins, Philadelphia, pp 983–1018Google Scholar
- 3.Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N, for the Japan Clinical Oncology Group (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91PubMedCrossRefGoogle Scholar
- 13.Negoro S, Fukuoka M, Nakamura S, Ikegami H, Sugiura T, Ariyoshi Y, Takada M, Yana T, Ogawa M (1995) Phase I–II study of amrubicin (SM-5887), a novel 9-aminoanthracycline, by iv administration for 3 consecutive days in patients with advanced non-small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 14:361Google Scholar
- 14.Japan Society for Cancer Therapy (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28:101–130Google Scholar
- 15.World Health Organization (1979) Handbook for reporting results of cancer treatment (WHO Offst Publication No. 48). World Health Organization, Geneva, SwitzerlandGoogle Scholar
- 16.Kaplan WH, Meier P (1952) Nonparametric estimation from incomplete observations. J Am Atat Assoc 53:583–612Google Scholar
- 18.Negoro S, Fukuoka M, Niitani H, Suzuki A, Nakabayashi T, Kimura M, Motomiya M, Kurita Y, Hasegawa K, Kuriyama T, Nishiwaki Y, Ogawa M, Nakao I, Saijo N, Obo K, Furue H, Ariyoshi Y, Shimokata K, Furuse K, Nakajima S, Irie K, Kimura I, Ogura T, Fujii M, Hara N, Hara Y, Nakano N, Araki J, Miyata Y, Taguchi T (1991) A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. Jpn J Cancer Chemother 18:1013–1019Google Scholar
- 22.Kirschling R, Jung S, Jett J (1994) A phase II study of taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol 13:326Google Scholar
- 23.Hesketh P, Crowley J, Burris HA 3rd, Williamson SK, Balcerzak SP, Peereboom D, Goodwin JW, Gross HM, Moore DF Jr, Livingston RB, Gandara DR (1999) Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. Cancer J Sci Am 5:237–241PubMedGoogle Scholar
- 24.Cormier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P, Wong D (1994) Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5:283–285PubMedGoogle Scholar